Fonte: Hepatology. Nome do evento: Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Unidades: FMRP, FM
Assuntos: HEPATITE C, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PESSOA, Mario G. et al. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis. Hepatology. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/hep.28800. Acesso em: 02 nov. 2024. , 2016APA
Pessoa, M. G., Ramalho, J. V. M., Alves, K., Cohen, D. E., Nunes, E. P., Cheinquer, H., et al. (2016). Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis. Hepatology. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/hep.28800NLM
Pessoa MG, Ramalho JVM, Alves K, Cohen DE, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Côrrea MCJ, Ferraz MLG, Lari S, Lui L, Tripathi R, Pilot-Matias T, Schulman N, Martinelli A de LC. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis [Internet]. Hepatology. 2016 ; 64 949A-950A.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1002/hep.28800Vancouver
Pessoa MG, Ramalho JVM, Alves K, Cohen DE, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Côrrea MCJ, Ferraz MLG, Lari S, Lui L, Tripathi R, Pilot-Matias T, Schulman N, Martinelli A de LC. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis [Internet]. Hepatology. 2016 ; 64 949A-950A.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1002/hep.28800
